Enzon Pharmaceuticals (OTCMKTS:ENZN) Posts Earnings Results

Enzon Pharmaceuticals (OTCMKTS:ENZN) released its quarterly earnings results on Monday. The biotechnology company reported ($0.84) earnings per share for the quarter, Zacks reports. The firm had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Price Performance

Shares of ENZN stock opened at $5.76 on Wednesday. The firm has a fifty day moving average of $6.06 and a two-hundred day moving average of $5.57. The firm has a market cap of $4.26 million, a P/E ratio of -0.84 and a beta of -0.03. Enzon Pharmaceuticals has a 1-year low of $1.50 and a 1-year high of $12.99.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.